BioTerm

Pharmaceuticals Ltd.

Revolutionary treatment for 

Pre-term labor & Labor induction 

Affects millions of women and newborn!

Bioterm Pharmaceuticals Ltd. is the developer of novel therapeutics for the treatment and prevention of pre-term labor and for the induction of labor that cause severe morbidity of millions of newborn worldwide.

The Company has patented the use of two molecules, its Preventerm molecule for the prevention of pre-term labor (PCT, pending) and its Inducterm molecule (approved patent) for labor induction.




   
Both molecules have been approved for therapy for unrelated indications, allowing BT a substantial acceleration of regulatory approvals. 

BT is currently seeking an equity investment of $ 7-9 million to complete Phase II clinical trials for Preventerm and pre-clinical trials for Inducterm, to broaden management, and to enhance marketing and business development activities in the U.S. and Europe.

Proven Efficacy

Lorem ipsum dolor sit amet, consectetur elit.

Read More

Certified Methods

Etiam pharetra, tellus sit amet congue vulputate.

Read More

Safety Tested

Cras elit nisl, rhoncus nec iaculis ultricies.

Read More

              

02/23/15
Suspendisse pharetra
Auctor pharetra. Nunc a sollicitudin est.


01/12/15
Donec vel neque
Fusce ornare elit nisl, feugiat bibendum lorem.


12/19/14
Curabitur ullamcorper
Auctor pharetra. Nunc a sollicitudin est.

Fusce ornare elit nisl, feugiat bibendum lorem.


10/23/14
Curabitur ullamcorper
Auctor pharetra. Nunc a sollicitudin est.

Auctor pharetra. Nunc a sollicitudin est.






All News

Log-in


 Name

 

Email

 LOG-IN